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Abstract 
Background: Multiple pathogeneses are involved in Alzheimer’s disease, such as amyloid-β 
accumulation, neuroinflammation and oxidative stress. The pathological impact of chronic 
cerebral hypoperfusion on Alzheimer’s disease is still poorly understood.  
Methods: APP23 mice were implanted to bilateral common carotid arteries stenosis with 
ameroid constrictors for slowly progressive chronic cerebral hypoperfusion. The effects of the 
administration of Twendee X were evaluated by behavioral analysis, immunohistochemical 
analysis and immunofluorescent histochemistry. 
Results: In the present study, chronic cerebral hypoperfusion, which is commonly found in 
aged Alzheimer’s disease, significantly exacerbated motor dysfunction of APP23 mice from 5 
months and cognitive deficit from 8 months of age, as well as neuronal loss, extracellular 
amyloid-β plaque and intracellular oligomer formations, and amyloid angiopathy at 12 months. 
Severe upregulations of oxidative markers and inflammatory markers were found in the 
cerebral cortex, hippocampus and thalamus at 12 months. Twendee X treatment (20 mg/kg/d, 
from 4.5 to 12 months) substantially rescued the cognitive deficit and reduced the above 
amyloid-β pathology and neuronal loss, alleviated neuroinflammation and oxidative stress.  
Conclusions: The present findings suggested a potential therapeutic benefit of Twendee X for 
Alzheimer’s disease with chronic cerebral hypoperfusion. 
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Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 69% in 
all dementia among the people older than 75 years. 1 Although pathogenesis of AD is complex, 
2-3 oxidative stress and inflammation are also considered to play important roles in the process 
of AD. 4-5 Chronic cerebral hypoperfusion (CCH) is a major cause of cognitive deficits and 
contributes to the progression of dementia. 6 Our recent studies showed that CCH strongly 
enhanced the AD pathology in mice, 7-8 which is appropriate to study the effects of CCH on 
cognitive impairments, AD pathology, neuroinflammatory and oxidative stress. Twendee X 
(TwX) is an anti-oxidant mixture that contains multiple ingredients, such as coenzyme Q10, 
ascorbic acid, L-glutamine and cystine. Our previous study demonstrated neuroprotective 
effects of TwX in an acute cerebral ischemia model in mice by reducing ischemic infarct and 
attenuating both oxidative stress and inflammatory markers. 9  
In the present study, therefore, we investigated a possible therapeutic effect of TwX on 
cognitive function, Aβ pathology, inflammatory and oxidative stresses in an AD mouse model 
with CCH. 
 
Materials and Methods 
Mouse model 
All procedures were approved by the guidelines of the Animal Committee of the Graduate 
School of Medicine and Dentistry of Okayama University (OKU-2014-095). APP23 mice 
overexpress human APP751 isoform carrying the Swedish double mutation (KM670/671NL) 
under the control of the murine Thy1 promoter. 10 APP23 male mice were obtained from Dr. 
Takashi Saito (RIKEN Brain Science Institute, Saitama, Japan) and maintained as hemizygotes 
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by mating APP23 male mice with C57BL/6J female mice (CLEA Japan, Tokyo, Japan). The 
offspring were genotyped using a PCR assay with DNA obtained from tail tissue samples. Wild 
type (non-transgenic) littermates were used as controls. Mice were housed in 12:12-hour light-
dark cycle with controlled temperature and free access to food and water.  
Four groups of mice were used in this study: wild type mice (WT + sham surgery, n = 10), 
APP23 group (APP23 + sham surgery, n = 10), CCH group (APP23 + CCH, n = 12) and TwX 
group (APP23 + CCH + TwX, n = 13). Groups comprised approximately equal numbers of 
male and female mice.  
For the CCH and TwX mice, ameriod constrictors (ACs) were applied to the bilateral 
common carotid arteries (BCCAs) at 4 months (M) of age, and cerebral blood flow (CBF) was 
measured with a laser-Doppler flowmeter (FLO-C1, Omegawave, Tokyo, Japan) before and 1, 
3, 7, 14 and 28 d after surgery as our previously report. 8  
TwX is a mixture containing multiple antioxidants, 9 such as coenzyme Q10 (3.6 wt%; 
AQUA Q10 P40-NF, Nissin Pharmaceutical, Tokyo, Japan), niacin amid (0.7 wt%), L-cystine 
(18.2 wt%), ascorbic acid (34.2 wt%), succinic acid (3.6 wt%), fumaric acid (3.6 wt%), L-
glutamine (34.6 wt%), and riboflavin (1.5 wt%; Bislase inj, Toa Eiyo, Tokyo, Japan). TwX was 
given to the mice in TwX group by oral gavage once daily 20 mg/kg per day from 4.5 M of age 
until sacrifice. 
 
Behavioral analysis 
Rotarod test was used to assess sensorimotor coordination of mice at ages of 2, 5, 7, 9 and 
11 M, and evaluation criteria is the time that mice spent on the rotating rod (MK670; 
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Muromachi Kikai Co., Tokyo, Japan) before falling as our previous report. 11 In brief, the 
rotarod test began with mice trying to stay on a rod rotating at 4 rpm, the speed was then 
increased to 40 rpm in a period of 60 seconds, and then kept the speed of 40 rpm. The latency 
to fall (up to a maximum of 400 seconds) was recorded. Six trials were performed in each 
measurement, and the best result was recorded. 
8-arm radial maze test was performed when mice aged 3, 6, 8, 10 and 12 M as our previous 
reports. 8, 12 Briefly, dietary restriction over 7 days was carried out which led to an 85% decrease of 
free-feeding body weight in all mice. Then mice were allowed to explore the baited arms of the 
maze for 10 min in 2 days habituation sessions. After adaptation, each mouse was left in the maze 
until either all pellets in 4 of the arms (1, 3, 4, and 7) were obtained or 5 min elapsed. Re-entry 
into the baited arms previously visited was recorded as a working memory error.  
 
Tissue preparation  
Mice aged 12 M were deeply anesthetized and then perfused with 20ml chilled phosphate-
buffered saline (PBS, pH 7.4), followed by 4% paraformaldehyde (PFA) in PBS. After post-
fixed in 4% PFA overnight, the brains were transferred into 10, 20 and 30% (wt/vol) sucrose in 
PBS for 24h, respectively. Coronal brain sections (20 μm) were cut on a cryostat at -20°C and 
mounted on silane-coated glass slides.  
 
Histochemistry and immunohistochemistry 
For Nissl staining, brain sections were incubated in 0.1% cresyl violet (CV) for 5 min at 
room temperature, dehydrated gradually in ethanol, and coverslipped with microcoverglass. 
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For single immunohistochemistry, after incubation in 0.3% hydrogen peroxide/methanol 
followed by 5% bovine serum albumin (BSA), the sections were strained overnight at 4°C with 
the following primary antibody: mouse anti-4G8 antibody (1:1000, Biolegend, San Diego, CA, 
USA), rabbit anti-A11 antibody (1:200, Invitrogen, Camarillo, CA, USA), goat anti-NLRP3 
antibody (1:100, Abcam, Cambridge, MA, USA), mouse anti-caspase-1 antibody (1:200, 
Adipogen, San Diego, CA, USA), goat anti-IL-1β antibody (1:100, R&D Systems, Minneapolis, 
MN, USA), rabbit anti-Iba-1 antibody (1:1000, Abcam), rabbit anti-TNFα antibody (1:200, 
Abcam), mouse anti-4-HNE antibody (1:40, JaICA, Shizuoka, Japan), mouse anti-8-OHdG 
antibody (1:20, JaICA) and rabbit anti- Nitrotyrosine antibody (1:200, Sigma-Aldrich, St. Louis, 
MO, USA). After washed with PBS, brain sections were treated with suitable biotinylated 
secondary antibodies (1:500; Vector Laboratories) at room temperature for 2 h. Then the 
sections were incubated with the avidin–biotin–peroxidase complex (VECTASTAIN Elite ABC 
Kit; Vector Laboratories) for 30 min and visualized with 3,3′-diaminobenzidine (DAB). 
Negative control sections were stained in the same way as described above except for the 
primary antibodies.  
3 sections per brain and 5 random selected regions were then analyzed with a light 
microscope (Olympus BX-51, Tokyo, Japan) for each measurement. Cerebral cortex (CTX), 
hippocampus (HI), and thalamus (TH) were measured for semiquantitative analysis of Nissl, 
A11, NLRP3, caspase-1, IL-1β, Iba-1, TNF-α, 4-HNE, 8-OHdG and nitrotyrosine staining 
intensity. The number of 4G8-positive plaques was expressed per 1 mm2. 
 
Double immunofluorescent histochemistry 
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After incubation in 5% BSA in PBS with 0.1% triton at room temperature for 1 h, the 
sections were incubated at 4 °C overnight with primary antibody. Antibodies were as follows: 
rabbit anti-A11 antibody (1:200, Invitrogen), goat anti-NLRP3 antibody (1:100, Abcam), 
mouse anti-Aβ40 antibody (1:100, Wako, Osaka, Japan), and mouse anti-αSMA antibody 
(1:100, Sigma-Aldrich). Following washes, sections were incubated with fluorescent secondary 
antibody, and the fluorescent signals were visualized by confocal microscope (LSM-780; Zeiss, 
Jena, Germany). 
 
Statistical analysis 
Data are expressed as mean ± standard deviation (SD). Statistical comparison was 
performed using one-way ANOVA analysis followed by Tukey-Kramer test. p < 0.05 was 
considered significant. 
 
Results 
Changes of CBF with ameroid constrictors implantation 
CBF gradually decreased in CCH and CCH + TwX groups from 1 d after surgery, reached 
a minimum at 7 d and then became stable until 28 d (Fig. 1B, # p < 0.01 vs APP23). There was 
no significant difference between CCH and TwX groups.  
 
Behavioral analysis after CCH 
CCH and CCH + TwX groups showed significant impairment of rotarod test at 5, 7, 9 and 
11 M after surgery compared to WT and APP23 groups, and TwX treatment (CCH + TwX) 
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significantly improved the rotarod time at 9 M compared with CCH group (Fig. 1C, *p < 0.05 
and **p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
In 8-arm radial maze test, CCH + TwX group showed significant improvement in errors at 8, 
10 and 12 M compared with CCH group (Fig. 1D, *p < 0.05 and **p < 0.01 vs WT; # p < 0.05 
vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
 
Neuronal loss after CCH 
Nissl staining showed significant lower density of neurons in subiculum, CA1, dentate 
gyrus (DG) and TH regions of 3 APP23 groups than in WT mice (Fig. 2A and 2B). However, 
TwX treatment significantly suppressed these neuropathological changes in the hippocampus 
and TH (Fig. 2B, **p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 
0.01 vs CCH).  
 
Parenchymal and vascular Aβ deposits 
The numbers of 4G8 positive-amyloid plaque (Fig. 3A, arrows) and A11-positive amyloid 
oligomer formation (Fig. 3A) were increased in CCH group, which were reduced by TwX 
treatment (Fig. 3A, 3D and 3E, *p < 0.05 and **p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs 
APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
Immunofluorescent analysis showed a colocalization of Aβ oligomer with NLRP3 both in 
Aβ plaque and neural cell (Fig. 3B). Aβ was also accumulated in cerebral vessels in CCH group 
than APP23 group, which was attenuated by TwX treatment (Fig. 3C).  
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Neuroinflammation after CCH  
NLRP3, caspase-1 and IL-1β were evidently increased in 3 APP23 groups (Fig. 4A, 5A 
and 6A), and TwX treatment significantly reduced such enhanced expressions of NLRP3, 
caspase-1 and IL-1β compared with CCH group (Fig. 4B, 5B and 6B, *p < 0.05 and **p < 0.01 
vs WT; # p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). The expression 
of the microglial Iba-1 was also increased in APP23 and APP23 + CCH, especially in the 
cerebral cortex, but was inhibited by TwX treatment (Fig. 7A and 7B, *p < 0.05 and **p < 0.01 
vs WT; # p < 0.05 vs APP23; $p < 0.05 vs CCH). The expression of pro-inflammatory cytokine 
marker TNF-α was increased significantly in the CTX, CA3 and TH, which was recovered by 
TwX treatment (Fig. 8A and 8B, *p < 0.05 and **p < 0.01 vs WT; # p < 0.05 and ## p < 0.01 vs 
APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
 
Oxidative stress change after CCH 
As shown in Fig. 9-11, 4-HNE, 8-OHdG and nitrotyrosine were increased in CTX and HI 
in 3 APP23 groups (Fig. 9A, 10A and 11A). These oxidative stress markers were all attenuated 
in CCH + TwX group compared with CCH group (Fig. 9B, 10B and 11B, *p < 0.05 and **p < 
0.01 vs WT; # p < 0.05 and ## p < 0.01 vs APP23; $p < 0.05 and $$p < 0.01 vs CCH). 
 
Discussion 
The present study showed that the administration of antioxidative mixture TwX improved 
motor coordination and working memory (Fig. 1), rescued hippocampal neuron loss (Fig. 2), 
decreased Aβ pathology (Fig. 3), and attenuated inflammatory reaction (Fig. 4-8) and oxidative 
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stress (Fig. 9-11) under CCH of APP23 mice. CCH is one major cause of vascular dementia, 
but is also an important risk factor of AD progression. 13 Our previous studies suggested that 
CCH enhanced neurodegenerative processes by promoting oxidative stress and 
neuroinflammation. 7-8  
Since hippocampal neurons are critically important for memory function, 14 the positive 
effect on working memory (Fig. 1D) was most likely a result of the protective mechanism of 
TwX against Aβ pathology under CCH (Fig. 2). In the present study, TwX significantly reduced 
amyloid plaques, Aβ oligomer formation, and CAA in the brain (Fig. 3). We also observed an 
anti-inflammatory effect of TwX by reducing the expression of these inflammatory markers 
(Fig. 4-8). Aβ oligomer induces the activation of the NLRP3 inflammasome, which then trigger 
downstream caspase-1, IL-1β, 15 microglia, 2 and TNF-α. 16 Thus the present results revealed 
the suppression of Aβ pathology based on the anti-inflammatory effects of TwX. 
Oxidative stress is an early event in AD, and also plays a key role in the progression of 
AD pathology. 17-19 As was expected, TwX showed a positive effection on an early stage of Aβ 
pathology with anti-oxidative mechanism in reducing the 4-HNE, 8-OHdG and nitrotyrosine 
(Fig. 9-11). Several studies have reported that antioxidants have potential therapeutic roles 
against AD. 20-22 Compared to a single ascorbic acid, the multiple antioxidant TwX showed 
synergistic effects on attenuating oxidative stress in an irradiation mouse model. 23 Our previous 
study also showed the neuroprotective effects of TwX in an acute cerebral ischemia mouse 
model. 9 
In summary, the present study revealed that CCH enhanced primary AD pathology of 
APP23, and TwX improved motor and memory functions, reduced such primary AD pathology 
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with suppressing inflammatory and oxidative stresses. 
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Figure Legends 
Fig. 1) Twendee X (TwX) improved behavioral deficits of Alzheimer’s disease (AD) mice 
model with chronic cerebral hypoperfusion (CCH). (A) Surgical implantation of ameroid 
constrictors on bilateral common carotid arteries. (B) Temporal profile of the cerebral blood 
flow measured by laser-Doppler flowmeter. (C) Analysis of motor function by rotarod test, and 
(D) working memory by 8-arm radial maze test (**p < 0.01 versus WT; #p < 0.05 versus APP23, 
##p < 0.01 versus APP23; $p < 0.05 versus APP23+CCH, $$p < 0.01 versus APP23+CCH). 
 
Fig. 2) (A) Nissl stainings in cerebral cortex (CTX), hippocampus (HI), and thalamus (TH) of 
AD mice model with CCH. (B) Quantitative analysis of Nissl staining intensity in the CTX, 
subiculum (Sub), CA1, dentate gyrus (DG), and TH (**p < 0.01 versus WT; #p < 0.05 versus 
APP23, ##p < 0.01 versus APP23; $p < 0.05 versus APP23+CCH, $$p < 0.01 versus APP23+CCH. 
Scale bar = 50 μm). 
 
Fig. 3) TwX ameliorated amyloid-β (Aβ) pathology in AD mice model with CCH. (A) 4G8 
immunolabelling of Aβ plaque (arrows) in CTX and HI, A11 immunolabelling of amyloid 
oligomer in CTX and TH. (B) Double immunofluorescence staining for A11 plus NLRP3 in Aβ 
plaques and cells. (C) Double immunofluorescence staining for α-SMA plus Aβ40. (D) 
Quantitative analysis of amyloid plaques in CTX and HI, and (E) quantitative analysis of A11 
staining intensity in CTX and TH (*p < 0.05 versus WT, **p < 0.01 versus WT; #p < 0.05 versus 
APP23, ##p < 0.01 versus APP23; $p < 0.05 versus APP23+CCH, $$p < 0.01 versus APP23+CCH. 
Scale bar = 50 μm). 
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Fig. 4) Immunohistochemical staining of NLRP3 in AD mice model with CCH. (A) NLRP3 
staining in CTX, HI and TH. (B) Quantitative analysis of NLRP3 (*p < 0.05 versus WT, **p < 
0.01 versus WT; #p < 0.05 versus APP23, ##p < 0.01 versus APP23; $p < 0.05 versus 
APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar = 50 μm). 
 
Fig. 5) Immunohistochemical staining of caspase-1 in AD mice model with CCH. (A) caspase-
1 staining in CTX, HI and TH. (B) Quantitative analysis of caspase-1 (*p < 0.05 versus WT, **p 
< 0.01 versus WT; #p < 0.05 versus APP23; $p < 0.05 versus APP23+CCH, $$p < 0.01 versus 
APP23+CCH. Scale bar = 50 μm). 
 
Fig. 6) Immunohistochemical staining of IL-1β in AD mice model with CCH. (A) IL-1β 
staining in CTX, HI and TH. (B) Quantitative analysis of IL-1β (*p < 0.05 versus WT, **p < 
0.01 versus WT; #p < 0.05 versus APP23, ##p < 0.01 versus APP23; $p < 0.05 versus 
APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar = 50 μm). 
 
Fig. 7) Immunohistochemical staining of Iba-1 in AD mice model with CCH. (A) Iba-1 staining 
in CTX, HI and TH. (B) Quantitative analysis of Iba-1 (*p < 0.05 versus WT, **p < 0.01 versus 
WT; #p < 0.05 versus APP23; $p < 0.05 versus APP23+CCH. Scale bar = 50 μm). 
 
Fig. 8) Immunohistochemical staining of TNF-α in AD mice model with CCH. (A) TNF-α 
staining in CTX, HI and TH. (B) Quantitative analysis of TNF-α (*p < 0.05 versus WT, **p < 
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0.01 versus WT; #p < 0.05 versus APP23, ##p < 0.01 versus APP23; $p < 0.05 versus 
APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar = 50 μm). 
 
Fig. 9) Immunohistochemical staining of 4-HNE in AD mice model with CCH. (A) 4-HNE 
staining in CTX, HI and TH. (B) Quantitative analysis of 4-HNE (**p < 0.01 versus WT; # p < 
0.05 versus APP23; $p < 0.05 versus APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar 
= 50 μm). 
 
Fig. 10) Immunohistochemical staining of 8-OHdG in AD mice model with CCH. (A) 8-OHdG 
staining in CTX, HI and TH. (B) Quantitative analysis of 8-OHdG (*p < 0.05 versus WT, **p < 
0.01 versus WT; #p < 0.05 versus APP23, ##p < 0.01 versus APP23; $p < 0.05 versus 
APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar = 50 μm). 
 
Fig. 11) Immunohistochemical staining of nitrotyrosine in AD mice model with CCH. (A) 
Nitrotyrosine staining in CTX, HI and TH. (B) Quantitative analysis of nitrotyrosine (*p < 0.05 
versus WT, **p < 0.01 versus WT; #p < 0.05 versus APP23, ##p < 0.01 versus APP23; $p < 0.05 
versus APP23+CCH, $$p < 0.01 versus APP23+CCH. Scale bar = 50 μm). 
 
